Pediatric Psoriasis Study

Study of Risankizumab in Pediatric Patients with Moderate to Severe Plaque Psoriasis

baby feet with red rash

 

AGE: 6-18 years old
SEX AT BIRTH: All
TYPE: Investigational Treatment Study
CONDITION: Plaque psoriasis
HEALTHY PARTICIPANTS: No
LOCATION: University Hospitals Medical Centers

Learn More About This Research Study

For more information, please contact study coordinator, Dr. Jordon Kahle at 216-844-7305 or complete the form below.

Study Purpose

The purpose of this study is to evaluate Risankizumab compared to Ustekinumab for the treatment of moderate to severe plaque psoriasis who are pediatric candidates for systemic therapy.

Who Can Participate

Participants between 6 and 18 years old with diagnosed with plaque psoriasis and do not have prior exposure to biologic medicines may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.

XXX-XXX-XXXX

STUDY ID#

  • STUDY20210431